{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:52:27Z","timestamp":1788630747374,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["(81873443, 82070162)"],"award-info":[{"award-number":["(81873443, 82070162)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Translational Research Grant of NCRCH","award":["(2020ZKZC04)"],"award-info":[{"award-number":["(2020ZKZC04)"]}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["(BK20201169)"],"award-info":[{"award-number":["(BK20201169)"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Key Science Research Project of Jiangsu Commission of Health","award":["(K2019022)"],"award-info":[{"award-number":["(K2019022)"]}]},{"name":"Frontier Clinical Technical Project of\u00a0Suzhou\u00a0Science and Technology\u00a0plan","award":["(SKY2022001)"],"award-info":[{"award-number":["(SKY2022001)"]}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","award":["(BCF-IBW-XY-20220930-13)"],"award-info":[{"award-number":["(BCF-IBW-XY-20220930-13)"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Suzhou\u00a0diagnosis and treatment project\u00a0of\u00a0Clinical\u00a0Key Diseases","award":["(LCZX202201)"],"award-info":[{"award-number":["(LCZX202201)"]}]},{"name":"the Priority Academic Program Development of Jiangsu Higher Education Institutions","award":["(PAPD)"],"award-info":[{"award-number":["(PAPD)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>B\/T mixed phenotype acute leukemia (MPAL), which represents only 2\u20133% of all MPAL cases, is classified as a high-risk leukemia subtype. Adults diagnosed with B\/T MPAL have a notably low 3-year survival rate, estimated at 20\u201340%. The rarity and undercharacterization of B\/T MPAL present substantial challenges in identifying an optimal treatment protocol. This report aims to shed light on this issue by presenting a case in which a patient with a complex karyotype was treated using a combination of venetoclax, azacitidine, and blinatumomab. This novel, chemo-free regimen resulted in the patient achieving both hematologic and molecular complete remission, with no severe organ or hematological toxicity observed. Notably, the patient continued to maintain molecular remission for 1\u00a0year following the transplantation. Based on these findings, the combination of venetoclax, azacitidine, and blinatumomab could be considered a potential therapeutic approach for B\/T MPAL patients, meriting further investigation.<\/jats:p>","DOI":"10.1007\/s00277-024-05644-9","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T10:03:23Z","timestamp":1708164203000},"page":"1397-1402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Successful treatment of a B\/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab"],"prefix":"10.1007","volume":"103","author":[{"given":"Shaoyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingya","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sifan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,17]]},"reference":[{"issue":"11","key":"5644_CR1","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","volume":"117","author":"E Matutes","year":"2011","unstructured":"Matutes E, Pickl WF, Van\u2019T Veer M et al (2011) Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 117(11):3163\u20133171","journal-title":"Blood"},{"issue":"11","key":"5644_CR2","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1038\/leu.2010.202","volume":"24","author":"OK Weinberg","year":"2010","unstructured":"Weinberg OK, Arber DA (2010) Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia 24(11):1844\u20131851","journal-title":"Leukemia"},{"issue":"1","key":"5644_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1365-2141.2009.08058.x","volume":"149","author":"H Gerr","year":"2010","unstructured":"Gerr H, Zimmermann M, Schrappe M, Reinhardt D et al (2010) Acute leukemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol 149(1):84\u201392","journal-title":"Br J Haematol"},{"issue":"7727","key":"5644_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-018-0436-0","volume":"562","author":"TB Alexander","year":"2018","unstructured":"Alexander TB, Gu Z, Mullighan CG et al (2018) The genetic basis and cell of origin of mixed phenotype acute leukemia. Nature 562(7727):373\u2013379","journal-title":"Nature"},{"issue":"21","key":"5644_CR5","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1182\/blood-2008-10-187351","volume":"113","author":"JE Rubnitz","year":"2009","unstructured":"Rubnitz JE, Onciu M, Pui CH et al (2009) Acute mixed lineage leukemia in children: the experience of St Jude Children\u2019s Research Hospital. Blood 113(21):5083\u20135089","journal-title":"Blood"},{"issue":"7","key":"5644_CR6","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/s41375-018-0058-4","volume":"32","author":"M Maruffi","year":"2018","unstructured":"Maruffi M, Sposto R, Oberley MJ, Kysh L et al (2018) Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia 32(7):1515\u20131528","journal-title":"Leukemia"},{"key":"5644_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00277-020-04354-2","volume":"100","author":"EO Rasekh","year":"2021","unstructured":"Rasekh EO, Osman R, Ibraheem D et al (2021) Acute lymphoblastic leukemia\u2013like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients. Ann Hematol 100:699\u2013707","journal-title":"Ann Hematol"},{"issue":"24","key":"5644_CR8","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","volume":"123","author":"K Beldjord","year":"2014","unstructured":"Beldjord K, Chevret S, Asnafi V et al (2014) Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood 123(24):3739\u20133749","journal-title":"Blood"},{"issue":"22","key":"5644_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1182\/blood.V128.22.178.178","volume":"128","author":"E Orgel","year":"2016","unstructured":"Orgel E, Oberley M, Li S et al (2016) Predictive value of minimal residual disease in WHO2016-defined mixed phenotype acute leukemia (MPAL). Blood 128(22):178","journal-title":"Blood"},{"issue":"Supplement_1","key":"5644_CR10","doi-asserted-by":"publisher","first-page":"5207","DOI":"10.1182\/blood-2019-127580","volume":"134","author":"J Yu","year":"2019","unstructured":"Yu J, Li Y, Xing H et al (2019) Clinical characteristics and outcome of biphenotypic acute leukemia: 10 cases report and literature review. Blood 134(Supplement_1):5207","journal-title":"Blood"},{"key":"5644_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40164-021-00239-w","volume":"10","author":"K Liu","year":"2021","unstructured":"Liu K, Li Y, Qiu S et al (2021) Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory\/relapse acute leukemias of ambiguous lineage, not otherwise specified. Exp Hematol Oncol 10:46","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"5644_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637951","volume":"26","author":"B Brethon","year":"2021","unstructured":"Brethon B, Lainey E, Caye-Eude A et al (2021) Case report: targeting 2 antigens as a promising strategy in mixed phenotype acute leukemia: combination of blinatumomab with gemtuzumab ozogamicin in an infant with a KMT2A-rearranged leukemia. Front Oncol 26(11):637951","journal-title":"Front Oncol"},{"key":"5644_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"D Courtney","year":"2020","unstructured":"Courtney D, DiNardo MD, Brian A, Jonas MD et al (2020) Azacitidine and venetoclax in previouslyuntreated acute myeloid leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"5644_CR14","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ et al (2018) Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378:1107\u20131120","journal-title":"N Engl J Med"},{"issue":"1","key":"5644_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317","journal-title":"Blood"},{"issue":"7","key":"5644_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617\u2013629","journal-title":"N Engl J Med"},{"issue":"18","key":"5644_CR17","doi-asserted-by":"publisher","first-page":"10957","DOI":"10.3390\/ijms231810957","volume":"23","author":"S Aumann","year":"2022","unstructured":"Aumann S, Shaulov A, Haran A et al (2022) The emerging role of venetoclax-based treatments in acute lymphoblastic leukemia. Int J Mol Sci 23(18):10957","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5644_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3390\/cancers14010150","volume":"14","author":"A Gibson","year":"2021","unstructured":"Gibson A, Trabal A, McCall D et al (2021) Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancers (Basel) 14(1):150","journal-title":"Cancers (Basel)"},{"issue":"9","key":"5644_CR19","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847","journal-title":"N Engl J Med"},{"issue":"14","key":"5644_CR20","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531","journal-title":"Blood"},{"issue":"6","key":"5644_CR21","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.bbmt.2016.02.013","volume":"22","author":"R Munker","year":"2016","unstructured":"Munker R, Brazauskas R et al (2016) Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia. Biol Blood Marrow Transplant 22(6):1024\u20131029","journal-title":"Biol Blood Marrow Transplant"},{"key":"5644_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.leukres.2016.04.002","volume":"45","author":"H Tian","year":"2016","unstructured":"Tian H, Xu Y et al (2016) Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. Leukemia Research 45:40\u201346","journal-title":"Leukemia Research"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05644-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05644-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05644-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T08:02:28Z","timestamp":1710662548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05644-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,17]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["5644"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05644-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3772060\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,17]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical trial was approved by the Ethics Committee of the First Affiliated Hospital of Soochow University. The patients\/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}